ArmaGen

ArmaGen, Inc. (earlier ArmaGen Technologies, Inc.) is a biotechnology company based in Calabasas, California, that develops therapies for severe neurological disorders. Its pipeline targets lysosomal storage disorders with central nervous system involvement, including Hurler syndrome (MPS I), Hunter syndrome (MPS II), metachromatic leukodystrophy, and Sanfilippo A and B syndromes, as well as other diseases with severe CNS manifestations. Named development candidates include AGT-181, AGT-182, AGT-183 and AGT-184.

The company's core work is engineering recombinant protein therapeutics that can cross the blood-brain barrier so that enzyme replacement therapies reach the central nervous system rather than treating only somatic disease manifestations. ArmaGen has described its position as resting on decades of scientific work in this area together with an intellectual property portfolio covering the approach. Its potential applications were also described as extending beyond rare lysosomal diseases to conditions such as Alzheimer's disease, Parkinson's disease and neuroinflammation.

ArmaGen became a wholly-owned subsidiary of Japan's JCR Pharmaceuticals Co., Ltd. in April 2020. JCR, which has its own blood-brain-barrier transport platform (J-Brain Cargo), cited ArmaGen's intellectual property position and expertise in lysosomal storage disorders and said it would use ArmaGen's US presence to support global development of its LSD portfolio.

Founding story

ArmaGen originated from UCLA research into how molecules such as insulin naturally cross the blood-brain barrier. The founder, identified in one account as Dr. William Partridge (also rendered Pardridge), concluded that the most effective route across the barrier was to exploit the body's own transport infrastructure to carry a therapeutic across, an approach likened to a Trojan horse. A separate account names James Callaway as founder. Early expansion was funded with small-business innovation and research grants before institutional venture capital was raised, which required overcoming investor skepticism built up over decades of failed attempts at blood-brain barrier penetration.

Business model

ArmaGen advances its pipeline through a combination of in-house development programs, out-licensing and collaboration agreements with pharmaceutical partners, and other partnering arrangements. An example is its worldwide licensing and collaboration agreement with Shire plc covering AGT-182 for Hunter syndrome. Since 2020 it has operated as a wholly-owned subsidiary of JCR Pharmaceuticals.

Revenue derives from licensing and collaboration agreements with pharmaceutical partners covering its blood-brain barrier delivery technology and enzyme replacement therapy candidates, together with early-stage government small-business research grants. Data providers estimate annual revenue in the $1M-$10M range as of August 2026.

Traction

A $17 million Series A closed in 2010 alongside a worldwide licensing and collaboration agreement with Shire plc for AGT-182. By 2013 the company had moved its lead programs through preclinical development and planned to file with the FDA in the first half of 2014 to begin human clinical testing; investors described it as clinical-stage. A further $10 million financing is listed by data providers as occurring in 2018. The company remains small, with headcount reported in the 1-10 range and roughly 7 employees as of August 2026.

Latest developments

JCR Pharmaceuticals announced completion of its acquisition of ArmaGen on April 27, 2020, following an initial announcement on March 26, 2020, with ArmaGen becoming a wholly-owned subsidiary. JCR said it would leverage ArmaGen's intellectual property and US presence for global development of its lysosomal storage disorder pipeline, including JR-141 for MPS II, with pivotal trials planned in the United States and Europe. ArmaGen CEO Mathias Schmidt was nominated as a candidate for the JCR board of directors ahead of the June 2020 shareholders' meeting.